| ISIN | US26923G2021 |
|---|---|
| TER | 0.01% |
| Replication | Synthetic |
| Distribution | Accumulating |
| Launch Year | 2014 |
| AUM | $0.02 billion |
| Provider | Virtus |
| Exchange | USA Stocks (USA) |
| Currency | USD |
| Country | USA |
| Type | ETF |
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration (FDA) for marketing.
Consult fund provider.
| Period | Return (%) |
|---|---|
| 1 Month | 6.68% |
| 3 Months | -9.74% |
| 6 Months | -7.94% |
| 1 Year | 1.82% |
| 3 Years | 52.65% |
| 5 Years | 22.90% |
| Since Inception | 122.61% |
Distribution: Accumulating
Volatility and risk metrics are calculated based on historical price movements.
This ETF is widely available on major European brokers like Trade Republic, Scalable, and DEGIRO.
Compare brokers →Exchange: USA Stocks (USA)
Currency: USD
Is this ETF accumulating?
Yes, it reinvests dividends.